Immunotherapy Advances,
Год журнала:
2022,
Номер
2(1)
Опубликована: Янв. 1, 2022
Immune
checkpoint
inhibitors
(ICI)
have
provided
new
hope
for
cancer
patients,
and
in
particular
patients
with
tumors
that
are
immunologically
active
classified
as
hot
tumors.
These
express
antigenic
tumor
microenvironment
(TME)
characteristics
make
them
potential
candidates
therapy
aim
to
reactivate
the
immune
response
such
anti-PD-1
anti-CTLA-4.
Examples
of
potentially
responsive
cancers
are,
melanoma,
non-small
cell
lung
several
other
metastatic
or
unresectable
genetic
instability:
DNA
mismatch
repair
deficiency
(dMMR),
microsatellite
instability-high
(MSI-H),
a
high
mutational
burden
(TMB).
Immunotherapy
using
is
typically
associated
adverse
events
(AEs)
milder
than
those
chemotherapy.
However,
significant
percentage
develop
short-term
immune-related
AEs
(irAEs)
which
range
from
mild
(~70%)
severe
cases
(~13%)
can
lead
modifications
inhibitor
some
cases,
death.
While
studies
investigated
mechanisms
behind
development
irAEs,
much
more
research
needed
understand
interventions
could
attenuate
while
maintaining
anti-tumor
intact.
Moreover,
identify
biomarkers
predict
likelihood
patient
developing
irAEs
would
be
great
clinical
importance.
Here
we
discuss
ramifications
their
useful
development.
Expert Review of Anticancer Therapy,
Год журнала:
2022,
Номер
22(8), С. 861 - 874
Опубликована: Июль 4, 2022
Introduction
Immune
checkpoint
inhibitors
(ICI)
are
now
utilized
as
a
standard
of
care
treatment
for
multiple
cancers,
including
in
both
the
metastatic
setting
well
earlier
stages
disease.
The
identification
unique
immune-related
adverse
events
(irAE)
that
occur
during
ICI
has
led
to
intense
research
identify
potential
risk
factors
and
biomarkers
may
assist
clinical
decision
making.
Although
initial
studies
were
primarily
advanced
stage
disease,
use
disease
adjuvant
therapies
requires
better
understanding
patient
stratification
mitigate
or
prevent
serious
irAE.Areas
covered
In
this
review,
we
set
out
describe
current
state
regarding
irAE
patients
with
non-small
cell
lung
cancer,
explore
barriers
irAE.
We
review
data
from
large
phase
3
trials
prospective
focusing
on
irAE,
many
retrospective
currently
form
bulk
our
Immunotherapy Advances,
Год журнала:
2022,
Номер
2(1)
Опубликована: Янв. 1, 2022
Immune
checkpoint
inhibitors
(ICI)
have
provided
new
hope
for
cancer
patients,
and
in
particular
patients
with
tumors
that
are
immunologically
active
classified
as
hot
tumors.
These
express
antigenic
tumor
microenvironment
(TME)
characteristics
make
them
potential
candidates
therapy
aim
to
reactivate
the
immune
response
such
anti-PD-1
anti-CTLA-4.
Examples
of
potentially
responsive
cancers
are,
melanoma,
non-small
cell
lung
several
other
metastatic
or
unresectable
genetic
instability:
DNA
mismatch
repair
deficiency
(dMMR),
microsatellite
instability-high
(MSI-H),
a
high
mutational
burden
(TMB).
Immunotherapy
using
is
typically
associated
adverse
events
(AEs)
milder
than
those
chemotherapy.
However,
significant
percentage
develop
short-term
immune-related
AEs
(irAEs)
which
range
from
mild
(~70%)
severe
cases
(~13%)
can
lead
modifications
inhibitor
some
cases,
death.
While
studies
investigated
mechanisms
behind
development
irAEs,
much
more
research
needed
understand
interventions
could
attenuate
while
maintaining
anti-tumor
intact.
Moreover,
identify
biomarkers
predict
likelihood
patient
developing
irAEs
would
be
great
clinical
importance.
Here
we
discuss
ramifications
their
useful
development.
